Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 14Breast 7Gynecologic 6Gastrointestinal 5Tumor-Agnostic 4Sarcoma 3Other solid neoplasm 3Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Genitourinary 2Dermatologic 2Myeloid 1

Conditions

Melanoma 2

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ceralasertib × Dermatologic × Clear all
NCT05061134 2025-07-31

MONETTE

AstraZeneca

Phase 2 Active not recruiting
194 enrolled 21 charts
Dermatologic

Melanoma

NCT03780608 2022-06-15

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Samsung Medical Center

Phase 2 Unknown
61 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡